Home / Health / HemeNext 2.0: Precision Blood Care for India
HemeNext 2.0: Precision Blood Care for India
15 Oct
Summary
- International conclave focuses on blood science for accessible patient care.
- Cancer burden highlights need for timely diagnosis and specialized treatment.
- Experts discuss genomics, CAR-T therapy, and pediatric blood disorder management.
Fortis Memorial Research Institute in Gurugram recently hosted HemeNext 2.0, a two-day international scientific conclave. The event convened Indian and global experts to bridge advancements in blood science with practical, affordable patient care. India's substantial cancer burden, with hundreds of thousands of new cases annually, underscores the critical need for precise diagnostics and sustained treatment access.
The conclave featured parallel scientific programs covering adult and pediatric hematology, genomics, and cellular therapies. Over 600 participants and faculty from the UK, US, Singapore, and India engaged in discussions on transforming research into clinical practice. Key themes included the role of genomics in refining diagnoses and guiding treatment decisions.
Discussions also explored cutting-edge therapies like CAR-T cell therapy, bone marrow transplantation, and precision diagnostics. Special attention was given to pediatric hematology, addressing childhood cancers, inherited disorders like thalassemia and sickle cell disease, and survivorship. Infectious disease management for immunocompromised patients was also a focus.
The conclave emphasized translating global research into India's clinical realities, focusing on informed treatment decisions, collaboration, and wider access. AI in diagnostics and research was also explored, alongside platforms for engaging emerging specialists and healthcare innovators.
